Tamoxifen ("Nolvadex"): a review

Area of Science:

• Oncology
• Endocrinology
• Pharmacology

Background:

• Tamoxifen has been a cornerstone in breast cancer management for over three decades.
• Its applications have expanded from advanced to early-stage disease, ductal carcinoma in situ, and chemoprevention.
• Tamoxifen is effective in both pre- and postmenopausal women, offering a broad therapeutic window.

Purpose of the Study:

• To review the established role and expanding indications of tamoxifen in breast cancer.
• To highlight the favorable efficacy and tolerability profile of tamoxifen.
• To discuss ongoing research regarding tamoxifen's optimal use and comparison with emerging therapies.

Main Methods:

• Review of clinical literature and established treatment guidelines.
• Analysis of tamoxifen's efficacy across different menopausal statuses and disease stages.
• Examination of tolerability data and safety profiles.

Main Results:

• Tamoxifen remains a primary endocrine therapy for estrogen-receptor-positive breast cancer due to its efficacy and tolerability.
• Its use is validated in advanced, early-stage breast cancer, ductal carcinoma in situ, and chemoprevention.
• Tamoxifen demonstrates consistent effectiveness in both pre- and postmenopausal women.

Conclusions:

• Tamoxifen's combination of efficacy and tolerability solidifies its position as a preferred hormonal treatment for most estrogen-receptor-positive breast cancers.
• Further studies are crucial to define optimal treatment duration and its comparative effectiveness against aromatase inhibitors.